Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | EOS100850 |
Trade Name | |
Synonyms | EOS-100850|EOS 100850|Inupadenant |
Drug Descriptions |
EOS100850 is an antagonist that selectively targets the A2A receptor and inhibits downstream signaling, which potentially induces an inflammatory response against tumor cells (Cancer Res 2019;79(13 Suppl):Abstract nr 4147). |
DrugClasses | Adenosine Targeting 23 |
CAS Registry Number | NA |
NCIT ID | C172109 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Carboplatin + EOS100850 + Pemetrexed Disodium | Carboplatin EOS100850 Pemetrexed Disodium | 0 | 1 |
EOS-448 + EOS100850 | EOS-448 EOS100850 | 0 | 1 |
EOS100850 | EOS100850 | 0 | 2 |
EOS100850 + Pembrolizumab | EOS100850 Pembrolizumab | 0 | 1 |
EOS100850 + unspecified CTLA4 antibody | EOS100850 unspecified CTLA4 antibody | 0 | 0 |